Toujeo Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The toujeo market research report is one of a series of new reports that provides toujeo market statistics, including toujeo industry global market size, regional shares, competitors with a toujeo market share, detailed toujeo market segments, market trends and opportunities, and any further data you may need to thrive in the toujeo industry. This toujeo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the rising prevalence of type 2 diabetes, an aging population, greater focus on chronic disease management, increased health awareness, and expansion of health insurance coverage. Major trends in the forecast period include technological advancements in insulin delivery devices, integration of digital health solutions, real-time blood glucose monitoring, research and development spending, and integration of IoT and smart technologies.

The increasing prevalence of diabetes is expected to drive the growth of the Toujeo market in the coming years. Diabetes is a chronic condition where the body struggles to regulate blood sugar due to insufficient insulin production or ineffective use of insulin. Factors such as unhealthy diets and sedentary lifestyles contribute significantly to the rise in diabetes cases worldwide. Toujeo helps manage blood sugar levels in people with type 1 and type 2 diabetes by releasing insulin steadily over 24 hours, typically through a once-daily injection. For example, in April 2024, the British Diabetic Association reported that approximately 4.4 million people in the UK have been diagnosed with diabetes, with an additional 1.2 million estimated cases of undiagnosed type 2 diabetes. Moreover, 167,822 new cases were recorded in 2022-23, illustrating the growing prevalence of the condition. As a result, the rising prevalence of diabetes is driving the demand for Toujeo.

The increasing adoption of insulin products is also expected to boost the growth of the Toujeo market. Insulin products include various formulations, such as rapid-acting, long-acting, and newer versions, designed to help regulate blood sugar levels in individuals with diabetes. The adoption of these products is rising due to the growing number of diabetes cases and improvements in treatment options, including newer insulin formulations that offer better control with fewer side effects. Toujeo (insulin glargine) is a basal insulin product known for providing consistent, long-lasting glucose control with a lower risk of hypoglycemia compared to other insulins. These benefits make it a preferred choice for both healthcare providers and patients, leading to its increased use. For instance, in February 2023, Novo Nordisk reported that its diabetes care products reached 36.3 million patients globally in 2022, marking a 5% increase from 2021. This growth was primarily driven by the GLP-1 franchise and the new-generation insulin products, which added a combined 3.2 million patients.

Rising healthcare investments are also expected to contribute to the growth of the Toujeo market. Healthcare investments refer to capital allocated to medical technologies, pharmaceuticals, healthcare facilities, and services. These investments are growing due to factors such as an aging population and advances in medical technology, both of which increase the demand for healthcare services and improve patient care. Investments in healthcare are crucial for funding clinical trials, expanding production, securing regulatory approvals, and enhancing distribution networks to ensure broader access to treatments such as Toujeo. For example, in January 2024, the National Institutes of Health reported that U.S. healthcare spending rose by 4.1% in 2022, reaching $4.5 trillion - outpacing the 3.2% increase observed in 2021. This increase in healthcare investments is expected to further drive the growth of the Toujeo market.

The key company operating in the toujeo market is Sanofi SA.

North America was the largest region in the toujeo market in 2024. The regions covered in toujeo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the toujeo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Toujeo is a long-acting insulin containing insulin glargine, designed to help control blood sugar levels in individuals with diabetes. Insulin glargine is a synthetic form of insulin that regulates blood glucose by providing a steady release of insulin over an extended period, typically up to 24 hours.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Toujeo is indicated for the treatment of type 1 diabetes, type 2 diabetes, and pediatric diabetes. Type 1 diabetes is an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas, resulting in little to no insulin production. Toujeo is available in prefilled pens and vials and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. It serves a variety of end users, including adults, geriatrics, and pediatric patients.

The toujeo market consists of sales of prefilled insulin pens, insulin detemir, insulin aspart, and insulin glargine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.